Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have earned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $51.5857.

Several equities analysts have recently issued reports on ZLAB shares. JPMorgan Chase & Co. cut their price target on Zai Lab from $46.00 to $39.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a research report on Monday, January 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, January 21st. UBS Group started coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Finally, Zacks Research cut Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd.

Zai Lab Trading Up 2.4%

ZLAB opened at $18.44 on Tuesday. Zai Lab has a 1-year low of $15.96 and a 1-year high of $44.34. The stock has a market capitalization of $2.06 billion, a PE ratio of -9.46 and a beta of 0.88. The firm has a 50-day moving average price of $18.08 and a two-hundred day moving average price of $25.88.

Insiders Place Their Bets

In related news, insider Rafael Amado sold 10,787 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total transaction of $188,017.41. Following the completion of the transaction, the insider owned 52,391 shares in the company, valued at approximately $913,175.13. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.96% of the stock is owned by insiders.

Institutional Trading of Zai Lab

A hedge fund recently bought a new stake in Zai Lab stock. SG Americas Securities LLC bought a new stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,754 shares of the company’s stock, valued at approximately $331,000. Institutional investors own 41.65% of the company’s stock.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.